Tweet
Syndicated from In Sequence RSS Feed
The homebrew test, currently in early-access testing and scheduled to be launched in October, is among the first commercial diagnostic tests to be offered on a next-generation sequencing platform. Though not the first genetic test for hypertrophic cardiomyopathy, the company claims it will be less expensive than rival assays. It is the first of many tests that GeneDx plans to offer on the Illumina GA.
More...
The homebrew test, currently in early-access testing and scheduled to be launched in October, is among the first commercial diagnostic tests to be offered on a next-generation sequencing platform. Though not the first genetic test for hypertrophic cardiomyopathy, the company claims it will be less expensive than rival assays. It is the first of many tests that GeneDx plans to offer on the Illumina GA.
More...